EGFR and HER2: Relevance in renal cell carcinoma

Eric Jonasch, Cheryl Lyn Walker

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With the improvement in our understanding of the molecular biology of renal cell carcinoma (RCC), a number of targeted therapeutics have become available for treatment of this disease, both FDA approved and in the experimental realm. The epidermal growth factor receptor (EGFR) family of molecules is an attractive target in RCC due to their overexpression on RCC tissue, and the ready availability of agents that target the pathway. This chapter summarizes the molecular biological information available for EGFR in RCC, preclinical work with blocking agents, and the clinical data on use of EGFR targeting strategies in RCC.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma
Subtitle of host publicationMolecular Targets and Clinical Applications
PublisherHumana Press
Pages287-303
Number of pages17
ISBN (Print)9781588297372
DOIs
StatePublished - 2009

Keywords

  • ErbB
  • Renal cell carcinoma
  • Resistance
  • Signaling
  • Targeted therapy

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'EGFR and HER2: Relevance in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this